Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency



Document title: Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency
Journal: Brazilian journal of medical and biological research
Database: PERIÓDICA
System number: 000350310
ISSN: 0100-879X
Authors: 1
2
Institutions: 1Universidade de Sao Paulo, Faculdade de Medicina, Sao Paulo. Brasil
2Universidade de Sao Paulo, Instituto de Ciencias Biomedicas, Sao Paulo. Brasil
Year:
Season: May
Volumen: 40
Number: 5
Pages: 601-613
Country: Brasil
Language: Inglés
Document type: Artículo
Approach: Caso clínico
English abstract A successful gene therapy clinical trial that also encountered serious adverse effects has sparked extensive study and debate about the future directions for retrovirus-mediated interventions. Treatment of X-linked severe combined immunodeficiency with an oncoretrovirus harboring a normal copy of the gc gene was applied in two clinical trials, essentially curing 13 of 16 infants, restoring a normal immune system without the need for additional immune-related therapies. Approximately 3 years after their gene therapy, tragically, 3 of these children, all from the same trial, developed leukemia as a result of this experimental treatment. The current understanding of the mechanism behind this leukemogenesis involves three critical and cooperating factors, i.e., viral integration, oncogene activation, and the function of the therapeutic gene. In this review, we will explore the causes of this unwanted event and some of the possibilities for reducing the risk of its reoccurrence
Disciplines: Medicina
Keyword: Oncología,
Genética,
Retrovirus,
Mutagénesis,
Síndrome de inmunodeficiencia combinada severa,
Terapia génica
Keyword: Medicine,
Oncology,
Retrovirus,
Mutagenesis,
Severe combined immunodeficiency syndrome,
Gene therapy,
Genetics
Full text: Texto completo (Ver HTML)